Merck & Co., Inc. Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount
Merck & Co., Inc. (MRK) had Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount of $395.00 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Debt and Equity Securities › Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount · last filed 2026-08-07
- 2026-06-30: Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount $395.00M.
- 2026-03-31: Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount $320.00M.
- 2025-12-31: Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount $292.00M.
- 2025-09-30: Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount $293.00M.
| Period end | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount |
|---|---|
| 2026-06-30 | $395.00M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $320.00M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $292.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $293.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $307.00M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $309.00M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $309.00M 10-K · filed 2025-02-25 |
| 2024-09-30 | $302.00M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $355.00M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $297.00M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $299.00M 10-K · filed 2024-02-26 |
| 2023-09-30 | $296.00M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $287.00M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $287.00M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $289.00M 10-K · filed 2023-02-24 |
| 2022-09-30 | $255.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $254.00M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $248.00M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $234.00M 10-K · filed 2022-02-25 |
| 2021-09-30 | $229.00M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $244.00M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $202.00M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $169.00M 10-K · filed 2021-02-25 |
| 2020-09-30 | $128.00M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $127.00M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $109.00M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $109.00M 10-K · filed 2020-02-26 |
| 2019-09-30 | $172.00M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $172.00M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $167.00M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |